Related Experiment Video
Updated: Feb 24, 2026
Endoscopic Ultrasound-Guided Biliary Drainage: Endoscopic Ultrasound-Guided Hepaticogastrostomy in Malignant Biliary Obstruction
Published on: March 25, 2022
Clinical Interpretation of Elevated CA 19-9 Levels in Obstructive Jaundice Following Benign and Malignant
Min Seong Kim1, Tae Joo Jeon2, Ji Young Park2
1Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Insights
Elevated carbohydrate antigen (CA) 19-9 levels after biliary drainage can help differentiate between benign and malignant pancreatobiliary diseases. Persistent high CA 19-9 suggests malignancy, aiding diagnosis in obstructive jaundice.
Area of Science:
- Gastroenterology and Hepatology
- Oncology
- Diagnostic Imaging
Background:
- Carbohydrate antigen (CA) 19-9 is a tumor marker often used in pancreatobiliary diseases.
- Obstructive jaundice can complicate the interpretation of CA 19-9 levels.
- Distinguishing benign from malignant causes of obstructive jaundice is clinically challenging.
Purpose of the Study:
- To evaluate the diagnostic value of CA 19-9 levels in pancreatobiliary diseases with obstructive jaundice.
- To determine the clinical interpretation of CA 19-9 levels before and after biliary drainage.
- To assess the utility of CA 19-9 in differentiating benign from malignant conditions.
Main Methods:
- Retrospective review of 114 patients with obstructive jaundice and pancreatobiliary disease.
- Analysis of serial CA 19-9 levels and biochemical values before and after biliary drainage.
- Comparison of CA 19-9 levels between benign (n=34) and malignant (n=80) disease groups.
Main Results:
- CA 19-9 elevation (>37 U/mL) was more frequent in malignant (90%) versus benign (59%) groups (p=0.001).
- Post-drainage, CA 19-9 remained elevated in 63% of malignant and 12% of benign cases (p<0.001).
- A CA 19-9 cut-off of 38 U/mL after drainage showed 62% sensitivity and 88% specificity for malignancy (AUC=0.787).
Conclusions:
- Persistent elevated CA 19-9 levels after biliary obstruction resolution suggest malignancy.
- A post-drainage CA 19-9 level >38 U/mL is a valuable indicator for differentiating benign from malignant pancreatobiliary disease.
- Consider malignancy in patients with persistently high CA 19-9 post-biliary drainage.
Background/Aims:
Elevated carbohydrate antigen (CA) 19-9 level may be unable to differentiate between benign and malignant pancreatobiliary disease with obstructive jaundice. The study aims to determine the clinical interpretation and the diagnostic value of CA 19-9 level in pancreatobiliary diseases with coexistent obstructive jaundice.
Methods:
We retrospectively reviewed the data of 981 patients who underwent biliary drainage due to obstructive jaundice following pancreatobiliary disease at Sanggye Paik Hospital for 5 years. 114 patients with serial follow-up data for CA 19-9 level were included in this study (80 patients with malignancy and 34 patients with benign diseases). We compared the levels of CA 19-9 levels and the biochemical value before and after biliary drainage.
Results:
The rate of CA 19-9 elevation (>37 U/mL) was significantly different between the benign group and the malignant group (59% vs. 90%, p=0.001). Despite the decrease in serum bilirubin after biliary drainage, CA 19-9 levels remained elevated in 12% of patients in the benign group and in 63% of patients in the malignant group (p<0.001). Finally, 12% of patients in the benign group turned out to have malignant disease. A receiver operating characteristic analysis provided a cut-off value of 38 U/mL for differentiating benign disease from malignant disease after biliary drainage (area under curve, 0.787; 95% confidence interval, 0.703 to 0.871; sensitivity, 62%; specificity, 88%).
Conclusions:
This study suggested that we should consider the possibility of malignant causes if the CA 19-9 levels remain high or are more than 38 U/mL after resolution of biliary obstruction.
Related Concept Videos
01:24Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:30Acute Pancreatitis II: Clinical Manifestations and Management
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:26Pancreatic Juice and Secretion
When acidic chyme from the stomach enters the duodenum, it triggers the release of secretin, a hormone that prompts pancreatic juice secretion. After a fatty meal, cholecystokinin, another hormone, stimulates gallbladder contraction and enhances enzyme-rich...
01:27Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include: